5Cogliano V,Baan R,Straif K,et al.Carcinogenicity of hu2man pap illomaviruses[J].LancetOncol,2005,6:204.
6Pao CC,ISeng CI,Lin CY,et al.Different expression of telomerase activity in human cervical intraepithelial neoplasia lesions[J].J Clin Oncol,1997,15(5):1932-1936.
7Torres LA,Pojo HG,Torres RA,et al.Cervical cancer:Current view of its epidemiology and risk factors[J].Gynecol Obstet Mex,2004,72:466-474.
8Ferrera A,Velema JP,Figueroa M,et al.Human papilomavirus infection,cervical dysplasia and invasive cervical cancer in Honduras:a case-control study[J].Int J Cancer,1999,82(6):799-802.
9Lang J H.To receive the global chanllenge and opportunity for preventing cervical cancer[J].Chin J Obstet Gynecol,2002,37:129-131.
10David B,Claire C,Mohamed M,et al.Deletion of the FHIT gene in neoplastic and invasive cervical lesions is related to high-risk HPV infection but is independent of histopathological features[J].Pathol,2000,192:502-510.
6Kornegay JR,Roger M,Davies PO,et al.International proficiency study of a consensus L1 PCR assay for the detection and typing of human papillomavirus DNA:evaluation of accuracy and intralaboratory and interlaboratory agreement[J].J Clin Microbiol,2003,41(3):1080～1086.
7Roneo G,Brezzi S,Carozzi F,et al.The new technologies for cervical cancer screening randomized controlled trial.An overview of results during the first phase of recruitment[J].Gynecol Oncol,2007,107 :S230- S232.
8Roneo G, Giorgi-Rossi P, Carozzi F, et al.New technologies for cervical cancer screening (NTCC)working group[J].Lancet Oncol, 2010 (11) : 249- 257.
9MeijerCJ, BerkhofJ, CastlePE, et al.Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women of 30 years and older[J].Int J Caneer, 2009 (124): 516-520.
10TORRES M,FRAILE L,ECHEVARRIA J,et al.Human Papillomavirus(HPV)Genotyping:Automation and Application in Routine Laboratory Testing[J].Open Virol J,2012,6:144-150.
